Journal Article
. 2008 Oct;26(34).
doi: 10.1200/JCO.2008.17.9705.

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer

Michael J Hassett 1 Melissa E Hughes  Joyce C Niland  Stephen B Edge  Richard L Theriault  Yu-Ning Wong  John Wilson  W Bradford Carter  Douglas W Blayney  Jane C Weeks  
Affiliations
  • PMID: 18955448
  •     37 References
  •     12 citations

Abstract

Purpose: To describe the frequency of chemotherapy use for hormone receptor (HR)-positive, lymph node (LN)-negative breast cancer from 1997 to 2004 at eight National Comprehensive Cancer Network institutions, to explore whether chemotherapy use varied over time and between institutions, and to identify factors associated with the decision to forego chemotherapy.

Patients And Methods: Among women younger than age 70 years with HR-positive, LN-negative breast cancer measuring more than 1 cm, we analyzed the frequency of chemotherapy use on a yearly basis. A multivariable logistic regression model assessed the relationship between receipt of chemotherapy and year of diagnosis, institution, tumor features, and patient characteristics. Interaction terms were added to the model, and stratified analyses were conducted to further explore the determinants of chemotherapy use.

Results: Fifty-five percent of 3,190 women received chemotherapy. Chemotherapy use was less common for patients with 1.1- to 2-cm tumors than for patients tumors greater 2 cm (47% v 87%, respectively; P < .01) and for women age 60 to 69 years versus women younger than age 50 years (24% v 76%, respectively; P < .01). On multivariable analysis, predictors independently associated with receiving chemotherapy included larger tumor size, higher grade, human epidermal growth factor receptor 2 overexpression, younger age, and institution (P < .01 for all). Institutions exhibited dramatically different rates of chemotherapy use (from 46% to 65%) and patterns of change in chemotherapy use over time (from a 79% relative increase to a 22% relative decrease).

Conclusion: Although institutions seemed to agree that not all women with HR-positive, LN-negative breast cancer need chemotherapy, there did not seem to be consensus regarding which women should get chemotherapy. Only prospective randomized controlled trials will conclusively establish which subtypes of HR-positive, LN-negative breast cancer benefit from chemotherapy.

Quality of breast cancer care: what do we know?
Jennifer L Malin, Mark A Schuster, Katherine A Kahn, Robert H Brook.
J Clin Oncol, 2002 Nov 01; 20(21). PMID: 12409338
Review.
Selecting high priority quality measures for breast cancer quality improvement.
Michael J Hassett, Melissa E Hughes, +6 authors, Jane C Weeks.
Med Care, 2008 Jul 31; 46(8). PMID: 18665055    Free PMC article.
Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
Xianglin L Du, Charles R Key, +2 authors, James S Goodwin.
Ann Intern Med, 2003 Jan 17; 138(2). PMID: 12529090    Free PMC article.
Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients.
Mauro Palazzi, Dolores De Tomasi, +13 authors, Filippo Bertoni.
Tumori, 2003 Feb 25; 88(6). PMID: 12597147
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers.
Stephen B Edge, Joyce C Niland, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2003 Oct 16; 95(20). PMID: 14559873
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M E Charlson, P Pompei, K L Ales, C R MacKenzie.
J Chronic Dis, 1987 Jan 01; 40(5). PMID: 3558716
Highly Cited.
Can comorbidity be measured by questionnaire rather than medical record review?
J N Katz, L C Chang, +2 authors, D W Bates.
Med Care, 1996 Jan 01; 34(1). PMID: 8551813
Highly Cited.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Outcomes assessment in the NCCN.
J C Weeks.
Oncology (Williston Park), 1998 Jan 16; 11(11A). PMID: 9430183
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
E G Mansour, R Gray, +4 authors, G Falkson.
J Clin Oncol, 1998 Nov 17; 16(11). PMID: 9817265
NCCN Internet-based data system for the conduct of outcomes research.
J C Niland.
Oncology (Williston Park), 1999 Feb 24; 12(11A). PMID: 10028507
Time trends in systemic adjuvant treatment for node-negative breast cancer.
N Hébert-Croteau, J Brisson, +3 authors, L Deschênes.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334531
Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network.
J Weeks.
Oncology (Williston Park), 1999 Jun 17; 13(5A). PMID: 10370922
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
Hyman B Muss, Susan Woolf, +11 authors, Cancer and Leukemia Group B.
JAMA, 2005 Mar 03; 293(9). PMID: 15741529
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A Goldhirsch, J H Glick, +4 authors, Panel members.
Ann Oncol, 2005 Sep 09; 16(10). PMID: 16148022
Highly Cited.
Update: NCCN breast cancer Clinical Practice Guidelines.
Robert W Carlson, Beryl McCormick.
J Natl Compr Canc Netw, 2005 Nov 11; 3 Suppl 1. PMID: 16280118
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network.
Caprice K Christian, Joyce Niland, +6 authors, Jane C Weeks.
Ann Surg, 2006 Jan 25; 243(2). PMID: 16432358    Free PMC article.
Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Linda C Harlan, Limin X Clegg, +2 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2006 Feb 18; 24(6). PMID: 16484696
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Robert W Carlson, Elizabeth Brown, +13 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2006 Mar 02; 4 Suppl 1. PMID: 16507275
Review.
NCCN outcomes research database: data collection via the Internet.
J C Niland.
Oncology (Williston Park), 2001 Feb 24; 14(11A). PMID: 11195402
Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.
X Du, J S Goodwin.
J Clin Oncol, 2001 Mar 07; 19(5). PMID: 11230491
Adjuvant therapy for breast cancer.
NIH Consens Statement, 2001 Aug 22; 17(4). PMID: 11512506
Review.
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
A Goldhirsch, J H Glick, +2 authors, H J Senn.
J Clin Oncol, 2001 Sep 18; 19(18). PMID: 11559719
Review.
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773285
Review.
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
B Fisher, J H Jeong, +4 authors, N Wolmark.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773294
Adjuvant therapy for breast cancer: practice patterns of community physicians.
Linda C Harlan, Jeffrey Abrams, +3 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2002 Mar 29; 20(7). PMID: 11919238
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG).
J Natl Cancer Inst, 2002 Jul 18; 94(14). PMID: 12122096
Cancer statistics, 2006.
Ahmedin Jemal, Rebecca Siegel, +4 authors, Michael J Thun.
CA Cancer J Clin, 2006 Mar 04; 56(2). PMID: 16514137
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Cancer statistics, 2007.
Ahmedin Jemal, Rebecca Siegel, +3 authors, Michael J Thun.
CA Cancer J Clin, 2007 Jan 24; 57(1). PMID: 17237035
Highly Cited.
Clinical application of the 70-gene profile: the MINDACT trial.
Fatima Cardoso, Laura Van't Veer, +3 authors, Martine J Piccart-Gebhart.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258980
Highly Cited.
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Angela Mariotto, Eric J Feuer, +3 authors, Jeffrey Abrams.
J Natl Cancer Inst, 2002 Nov 07; 94(21). PMID: 12419789
Factors influencing treatment recommendations in node-negative breast cancer.
Elisabeth Edstrom Elder, Sally Baron Hay, Katrina Moore.
J Oncol Pract, 2011 May 03; 7(1). PMID: 21532807    Free PMC article.
Surgery of the primary tumor does not improve survival in stage IV breast cancer.
Laura Dominici, Julie Najita, +8 authors, Mehra Golshan.
Breast Cancer Res Treat, 2011 Jun 30; 129(2). PMID: 21713372    Free PMC article.
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
H Wong, S Lau, +6 authors, T Yau.
Med Oncol, 2011 Oct 11; 29(3). PMID: 21983862
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Jennifer J Griggs, Sarah T Hawley, +8 authors, Steven J Katz.
J Clin Oncol, 2012 Aug 08; 30(25). PMID: 22869890    Free PMC article.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
NIR-driven Smart Theranostic Nanomedicine for On-demand Drug Release and Synergistic Antitumour Therapy.
Pengfei Zhao, Mingbin Zheng, +6 authors, Lintao Cai.
Sci Rep, 2015 Sep 25; 5. PMID: 26400780    Free PMC article.
Treatment of Breast Cancer in the Elderly.
Rachel A Freedman.
Curr Oncol Rep, 2015 Sep 29; 17(11). PMID: 26412227
Review.
A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.
Qiao Li, Zhao Yang, +8 authors, Pin Zhang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100275    Free PMC article.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
Allison W Kurian, Kevin C Ward, +5 authors, Steven J Katz.
JAMA Oncol, 2020 Feb 07; 6(4). PMID: 32027353    Free PMC article.
Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
Jamal Zekri, Meteb Al-Foheidi, +2 authors, Ayman Rasmy.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447239    Free PMC article.